Compare MGYR & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGYR | CRDL |
|---|---|---|
| Founded | 1922 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.2M | 123.9M |
| IPO Year | 2021 | 2017 |
| Metric | MGYR | CRDL |
|---|---|---|
| Price | $21.71 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.55 |
| AVG Volume (30 Days) | 6.8K | ★ 557.5K |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 26.83 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.03 | $0.88 |
| 52 Week High | $23.99 | $2.34 |
| Indicator | MGYR | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | 35.45 |
| Support Level | $16.88 | $0.95 |
| Resistance Level | $23.99 | $1.10 |
| Average True Range (ATR) | 0.74 | 0.07 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 34.84 | 36.07 |
Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.